Enveric Biosciences, Inc. (NASDAQ:ENVB) Short Interest Update

Enveric Biosciences, Inc. (NASDAQ:ENVB) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 22,872 shares, a growth of 77.7% from the August 31st total of 12,873 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 44,964 shares, the days-to-cover ratio is presently 0.5 days.

Enveric Biosciences Stock Up 3.3%

Shares of NASDAQ ENVB traded up $0.05 during midday trading on Wednesday, hitting $1.50. The company had a trading volume of 57,057 shares, compared to its average volume of 63,212. Enveric Biosciences has a twelve month low of $1.17 and a twelve month high of $13.25. The business has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.89.

Enveric Biosciences (NASDAQ:ENVB) last issued its earnings results on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.

Analyst Ratings Changes

Several analysts have recently commented on ENVB shares. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc is a biotechnology company focused on developing novel therapeutics for mental health and neurological disorders. The company’s research platform is centered on neuroplastogenic compounds, including synthetic molecules inspired by psychedelic medicines, with the goal of addressing conditions such as depression, anxiety and addiction.

Enveric’s pipeline has included EB-373, an investigational synthetic prodrug of psilocin designed for potential use in treating mental health conditions.